PULM 8-K SEC Filing Analysis

Latest settled — T+5d

PULM ▲ +7.20% at T+5d

NEUTRAL call ✓ call won +7.20% · α vs SPY +6.24% · entry $1.25 → $1.34

Next anchor: T+20d in 5d

Last close $1.42 (close Jun 8) · +13.60% from $1.25 entry

Entry anchored
May 14, 10:50 AM ET
via Databento tick

T+1d

+0.80%

call +0.80% · α +0.86%

$1.26

settled 23d ago

T+5d

+7.20%

call +7.20% · α +6.24%

$1.34

settled 19d ago

T+20d

—

call — · α —

—

in 5d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Pulmatrix reported Q1 2026 results with no revenue and a net loss of $1.2M, improved from $1.8M a year ago. Cash stood at $3.3M with a going-concern qualification. The company is pursuing a merger with Eos SENOLYTIX, expected to close in Q3 2026, having raised $1M in a private placement. This is a minimal-event filing for a pre-revenue entity reliant on merger completion.

Actionable Insight

The stock will move on merger execution, not quarterly results. Monitor for regulatory and stockholder approvals for the Eos merger; failure to close would likely lead to cash depletion and delisting risk. The $1M preferred placement provides a short cash runway.

Key Facts

Net loss of $1.2M for Q1 2026 vs $1.8M in Q1 2025, improvement of 35%
Cash and equivalents of $3.3M as of March 31, 2026, down from $4.1M at year-end 2025
Financial statements prepared on a going-concern basis
All clinical development on hold while seeking to license or monetize assets
Merger agreement with Eos SENOLYTIX signed March 26, 2026; expected close Q3 2026
Raised $1M gross proceeds from private placement of Series B Convertible Preferred Stock

Financial Impact

Net loss improved to $1.2M from $1.8M; no revenue. Cash burn of ~$0.8M during the quarter.

cashnet loss

Risk Factors

Merger with Eos may not close, leaving the company without a viable path forward
Cash of $3.3M is insufficient for long-term operations without additional funding or deal completion
Ongoing going-concern qualification increases bankruptcy risk

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

86% bullish (7 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001493152-26-023367
Document: form8-k.htm	0001493152-26-023367
Document: 0001493152-26-023367-index-headers.html	0001493152-26-023367
Document: 0001493152-26-023367-index.html	0001493152-26-023367
Document: 0001493152-26-023367.txt	0001493152-26-023367
8-K Data (Synthetic)	0001493152-26-023367

4 reports for PULM

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for PULM — sortable, filterable
	Type				Now
Jun 5, 2026 4d ago	425 NEUTRAL ★ 4/10	$1.31 awaiting T+1	awaiting T+1	—	$1.42 (+8.81%)
Jun 4, 2026 5d ago	S-3 BEARISH ★ 5/10	$1.32 $1.33	▼ −0.76%	▼ −3.36%	$1.42 (−7.58%)
May 15, 2026 25d ago	8-K NEUTRAL ★ 4/10	$1.25 $1.26	▲ +0.80%	▲ +0.86%	$1.42 (+13.60%)
Apr 21, 2026 7w ago	8-K NEUTRAL ★ 5/10	$1.38 $1.40	▲ +1.45%	▲ +0.43%	$1.42 (+2.90%)

US Market Status

Market Closed — Opens in 6h 58m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access